151P Clinical outcome and preliminary immune analysis of phase II clinical trial of combination of tocilizumab with ipilimumab and nivolumab for patients with treatment naïve metastatic melanoma. (December 2022)

Record Type:: Journal Article
Title:: 151P Clinical outcome and preliminary immune analysis of phase II clinical trial of combination of tocilizumab with ipilimumab and nivolumab for patients with treatment naïve metastatic melanoma. (December 2022)
Main Title:: 151P Clinical outcome and preliminary immune analysis of phase II clinical trial of combination of tocilizumab with ipilimumab and nivolumab for patients with treatment naïve metastatic melanoma
Authors:: Montazari, E.J.J.
Abdel-Wahab, N.
Johnson, D.
Spillson, C.
Elsayes, K.M.
Duan, F.
Yadav, S.
Allison, J.
Sharma, P.
Diab, A.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100263 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24685.xml